INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 46h ago
HOUSE PTR6h ago
SEC 13F6h ago
ROBINHOOD CHAIN6h ago
SEC FORM 4/Grant or awardVerified data

Peterson Kristine reported MLYS

Director · Mineralys Therapeutics, Inc. · Common Stock

Side
A
Value
—
Shares
12.4K
Price
—
Executed
Oct 19, 2026
Disclosed
Oct 20, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Oct 19 executedOct 20, 2026 disclosed

MLYS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · MLYS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    PK
    Peterson KristineDirector
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    		A—
    16.6K sh
    		Oct 19, 2026Oct 20, 2026
    traded Oct 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CL
    Coats LonnelDirector
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    		A—
    12.4K sh
    		Oct 19, 2026Oct 20, 2026
    traded Oct 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CL
    Coats LonnelDirector
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    		A—
    16.6K sh
    		Oct 19, 2026Oct 20, 2026
    traded Oct 19, 2026
    		+1dSEC FORM 4

    Evidence

    31
    ST
    Slingsby Brian TaylorDirector
    MLYSMineralys Therapeutics, Inc.
    Open-market sale
    		SELL$3.01M
    104.3K sh
    		Sep 22, 2026Sep 24, 2026
    traded Sep 22, 2026
    		+2dSEC FORM 4

    Evidence

    0
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    7,438 sh
    		Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    		+1dSEC FORM 4

    Evidence

    2
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$98K
    7,438 sh
    		Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    		+1dSEC FORM 4

    Evidence

    13
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$209K
    7,438 sh
    		Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    		+1dSEC FORM 4

    Evidence

    0
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    7,437 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    2
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$98K
    7,437 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    13
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$193K
    7,437 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    9
    FJ
    Ferguson James J. IIIChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    		A—
    135.0K sh
    		Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RM
    Rodman David MalcomChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    2,170 sh
    		Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    		+2dSEC FORM 4

    Evidence

    6
    RM
    Rodman David MalcomChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$59K
    2,170 sh
    		Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    		+2dSEC FORM 4

    Evidence

    9
    FJ
    Ferguson James J. IIIChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    		A—
    102.4K sh
    		Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RM
    Rodman David MalcomChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$35K
    2,170 sh
    		Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    		+2dSEC FORM 4

    Evidence

    20
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$1.38M
    104.1K sh
    		Jun 26, 2026Jun 30, 2026
    traded Jun 26, 2026
    		+4dSEC FORM 4

    Evidence

    19
    CJ
    Congleton JonDirector, Chief Executive Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$456K
    17.0K sh
    		Jun 30, 2026Jun 30, 2026
    traded Jun 30, 2026
    		+0dSEC FORM 4

    Evidence

    26
    CJ
    Congleton JonDirector, Chief Executive Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.50M
    58.0K sh
    		Jun 30, 2026Jun 30, 2026
    traded Jun 30, 2026
    		+0dSEC FORM 4

    Evidence

    11
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    104.1K sh
    		Jun 26, 2026Jun 30, 2026
    traded Jun 26, 2026
    		+4dSEC FORM 4

    Evidence

    41
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2.70M
    104.1K sh
    		Jun 26, 2026Jun 30, 2026
    traded Jun 26, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001508596-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 19, 2026
    Published
    Oct 20, 2026
    Ingested by INSIDER
    Nov 5, 02:10 UTC
    Last re-read
    Nov 5, 02:10 UTC

    Extracted facts

    Filer
    Peterson Kristine
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Mineralys Therapeutics, Inc.
    Ticker
    MLYS
    Shares
    12.4K
    Price per share
    $0
    Execution date (reported)
    Oct 19, 2026
    Owned after transaction
    12.4K shares
    Days from execution to publication
    1

    What this establishes

    Peterson Kristine filed this Form 4 reporting a grant or award of MLYS on Oct 19, 2026. It became public on Oct 20, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Peterson Kristinecik:0001508596
    Issuer
    Mineralys Therapeutics, Inc.cik:0001933414

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.